Immunoprecise Antibodies Ltd (IPA) — Capital Reinvestment Ratio
Immunoprecise Antibodies Ltd (IPA) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). Check Immunoprecise Antibodies Ltd (IPA) tangible net worth to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Immunoprecise Antibodies Ltd Capital Reinvestment Ratio (2016–2016)
This chart tracks Immunoprecise Antibodies Ltd's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Immunoprecise Antibodies Ltd.
Annual Capital Reinvestment Ratio for Immunoprecise Antibodies Ltd (2016–2016)
Year-by-year Capital Reinvestment Ratio for Immunoprecise Antibodies Ltd from 2016 to 2016. See Immunoprecise Antibodies Ltd (IPA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.06x | $284.09K | $17.48K | — |